Interstitial pneumonitis after treatment with pemetrexed: A rare event?

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 84-88

  Hochstrasser, Andreas ^a   Benz, Gabriel ^a   Joerger, Markus ^a   Templeton, Arnoud ^a   Brutsche, Martin ^a   Frh, Martin ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Adenocarcinoma; Interstitial lung disease; Lung; Pemetrexed; Pneumonitis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; PEMETREXED; STEROID;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CASE REPORT; DISEASE SEVERITY; DRUG FATALITY; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RARE DISEASE; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; GLUTAMATES; GUANINE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84857473726     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000336131     Document Type: Article

References (26)

1. Disel U, Pavdas S, Yavuz S, Karakoc E: Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Chemotherapy 2010; 56: 89-93.
2. Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B: Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56: 69-70.
3. Joerger M, Omlin A, Cerny T, Fruh M: The role of pemetrexed in advanced non-smallcell lung cancer: Special focus on pharmacology and mechanism of action. Curr Drug Targets 2010; 11: 37-47.
4. Goldman ID, Zhao R: Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29: 3-17.
5. Calvert AH: Biochemical pharmacology of pemetrexed. Oncology (Williston Park) 2004; 18: 13-17.
6. Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with thirdspace fluid. Clin Cancer Res 2010; 16: 2872-2880.
7. Brandes JC, Grossman SA, Ahmad H: Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: Presentation of a case and review of the literature. Cancer Invest 2006; 24: 283-287.
8. Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR, et al: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65: 640-645.
9. Stahel RA, Felley-Bosco E, Opitz I, Weder W: Malignant pleural mesothelioma. Future Oncol 2009; 5: 391-402.
10. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE: A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic nonsmall cell lung or esophageal cancer. Clin Cancer Res 2007; 13: 515-522.
11. Brade A, Bezjak A, MacRae R, Laurie SA, Pond GR, Wang L, Dick C: A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIa/b non-small cell lung cancer (abstract 7550). J Clin Oncol 2008;(suppl 26).
12. Brade AM, Bezjak A, MacRae RM, Laurie SA, Wang L, Capobianco S: A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIa/b nonsmall cell lung cancer (abstract 7087). J Clin Oncol 2010; 28(suppl 15).
13. Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A: Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol 2011; 6: 927-933.
14. Ma S, Xu Y, Ji Y, Sun X, Cheng J, Du X: Concomitant pemetrexed/ carboplatin chemotherapy and 3rd conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary results of a phase II study (abstract 7092). J Clin Oncol 2010; 28(suppl 15).
15. Vokes EE, Senan S, Treat JA, Iscoe NA: Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III nonsmall-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009; 10: 193-198.
16. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
17. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20: 3533-3544.
18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
19. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ: Phase II study of pemetrexed with and without folic acid and vitamin B 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-1561.
20. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EE: Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol 2011; 22: 2501-2507.
21. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M: Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B 12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14: 4206-4212.
22. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
23. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC: Pemetrexed-induced pneumonitis: A case report. Clin Lung Cancer 2009; 10: 364-366.
24. Grove ML, Hassell AB, Hay EM, Shadforth MF: Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001; 94: 309-319.
25. Clewes AR, Dawson JK: Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 1059-1060, author reply 1060.
26. Kim YJ, Song M, Ryu JC: Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009; 256: 183-190.